These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38969067)

  • 1. Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.
    Poston TB; Girardi J; Polson AG; Bhardwaj A; Yount KS; Jaras Salas I; Trim LK; Li Y; O'Connell CM; Leahy D; Harris JM; Beagley KW; Goonetilleke N; Darville T
    Mucosal Immunol; 2024 Jul; ():. PubMed ID: 38969067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
    Li W; Murthy AK; Lanka GK; Chetty SL; Yu JJ; Chambers JP; Zhong G; Forsthuber TG; Guentzel MN; Arulanandam BP
    Vaccine; 2013 Nov; 31(48):5722-8. PubMed ID: 24096029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.
    Murthy AK; Cong Y; Murphey C; Guentzel MN; Forsthuber TG; Zhong G; Arulanandam BP
    Infect Immun; 2006 Dec; 74(12):6722-9. PubMed ID: 17015458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
    Li W; Murthy AK; Guentzel MN; Seshu J; Forsthuber TG; Zhong G; Arulanandam BP
    J Immunol; 2008 Mar; 180(5):3375-82. PubMed ID: 18292563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of an enzymatically inactive CPAF mutant vaccination in Chlamydia muridarum genital tract infection.
    Chen H; Peng B; Yang C; Xie L; Zhong S; Sun Z; Li Z; Wang C; Liu X; Tang X; Zhong G; Lu C
    Microb Pathog; 2021 Nov; 160():105137. PubMed ID: 34390765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlamydia trachomatis outer membrane complex protein B (OmcB) is processed by the protease CPAF.
    Hou S; Lei L; Yang Z; Qi M; Liu Q; Zhong G
    J Bacteriol; 2013 Mar; 195(5):951-7. PubMed ID: 23222729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.
    Murphey C; Murthy AK; Meier PA; Neal Guentzel M; Zhong G; Arulanandam BP
    Cell Immunol; 2006 Aug; 242(2):110-7. PubMed ID: 17116296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.
    Olsen AW; Theisen M; Christensen D; Follmann F; Andersen P
    PLoS One; 2010 May; 5(5):e10768. PubMed ID: 20505822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective anti-chlamydial vaccine regimen-induced CD4+ T cell response mediates early inhibition of pathogenic CD8+ T cell response following genital challenge.
    Murthy AK; Wright-McAfee E; Warda K; Moy LN; Bui N; Musunuri T; Manam S; Chako CZ; Ramsey KH; Li W
    Pathog Dis; 2024 Feb; 82():. PubMed ID: 38684476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
    García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
    J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV.
    Chinnakannan SK; Cargill TN; Donnison TA; Ansari MA; Sebastian S; Lee LN; Hutchings C; Klenerman P; Maini MK; Evans T; Barnes E
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32295168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.
    Li W; Murthy AK; Guentzel MN; Chambers JP; Forsthuber TG; Seshu J; Zhong G; Arulanandam BP
    Infect Immun; 2010 Sep; 78(9):3942-9. PubMed ID: 20605976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.